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A B S T R A C T
Purpose: Levetiracetam (LEV) therapeutic range (20–40 mg/L) and potential drug interactions were
assessed in people with epilepsy (PWE).
Method: Fifty-two PWE had LEV and concomitant medications [carbamazepine (CBZ); valproate (VPA);
lamotrigine (LTG)] blood levels measured and compared to seizure activity. Lacosamide (LCM) levels
were unavailable. Adopted therapeutic ranges were: 20–40 mg/L – LEV; 25–50 mmol/L – total CBZ; 6–
13 mmol/L – free CBZ; 300–750 mmol/L – total VPA; 30–75 mmol/L – free VPA; and 40–60 mmol/L – LTG.
Seizure-freedom was assessed and patients followed for almost two years.
Results: 23 of 52 PWE (44%) used LEV monotherapy and 16/23 (70%) had ‘therapeutic’ LEV with 13/16
(81%) seizure-free. 29 of 52 (56%) used polytherapy and 16/29 (55%) had ‘therapeutic’ LEV with 7/16
(44%) seizure-free. 11 of 29 (38%) used CBZ: 4/11 (36%) had therapeutic mean LEV levels and 7/11 (64%)
were seizure-free. Fourteen (48%) used VPA: 9/14 (64%) had therapeutic mean LEV levels and 8/14 (57%)
were seizure-free. 13 of 29 (45%) used LTG: 8/13 (62%) had therapeutic mean LEV levels and 5/13 (38%)
were seizure-free. LEV did not alter CBZ, but CBZ affected LEV. LEV elevated VPA free levels but not VPA
total levels. Dosage/concentration was lowered with polytherapy.
Conclusion: LEV range (20–40 mg/L) assisted epilepsy management and anti-epileptic medication
interactions were suggested with polytherapy thus possibly explaining the impaired efﬁcacy of LEV with
polytherapy.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Levetiracetam (LEV) is approved as monotherapy for focal
epilepsy and add-on therapy for myoclonic and tonic-clonic
seizures.1 It is absorbed quickly and almost completely over a
range of oral doses2 and is not metabolised via the hepatic
cytochrome p450 system. Two thirds are excreted unaltered in
the urine, while the rest is excreted in the urine as an inactive
metabolite L057, formed by enzymatic hydrolysis of the acetamide
group.2 It has minimal protein binding3 and a half-life of 6–8 h.
Previous studies have reported no signiﬁcant interactions
between LEV and other anti-epileptic medications (AEMs).4–6 It
has also been shown that the rate of LEV metabolism is stimulated
to some extent by major enzyme-inducing AEMs, such as* Corresponding author at: Suite 5, Level 6, 12 Thomas Street, Chatswood, New
South Wales 2067, Australia. Tel.: +61 2 9411 4991; fax: +61 2 9413 1353.
E-mail addresses: roy@royberan.com, research@royberan.com (R.G. Beran).
http://dx.doi.org/10.1016/j.seizure.2014.02.003
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights recarbamazepine (CBZ), phenytoin and phenobarbital and that LEV
clearance is 25–37% higher in patients who are taking enzyme-
inducing AEMs.7
Serum LEV levels are not widely advocated and currently
performed mainly for the purposes of monitoring those with
impaired renal function8 and the elderly.9 Serum and plasma LEV
levels have been used for pharmacokinetic and tolerability
studies.9–11
An LEV reference range of 12–46 mg/mL12 has been offered but
the relationship between LEV concentrations and efﬁcacy was not
established, hence monitoring of plasma LEV levels is not
recommended.13 This paper reports the efﬁcacy of an LEV range
of 20–40 mg/L in people with epilepsy (PWE) and the potential for
signiﬁcant interactions with concomitant AEMs.
2. Methods
LEV levels for 52 PWE were prospectively measured as part of
ongoing clinical management, within the private practice setting ofserved.
Table 1
Patient demographics.
Age 19–69 years (42 years  14)
Gender
Male 21
Female 31
Type of seizures
Focal 27
Primary generalised 21
Unclassiﬁed 4
Number of medications
1 (LEV) 23
2 (CBZ, LEV) 7
2 (VPA, LEV) 6
2 (LTG, LEV) 4
2 (LEV, LCM) 1
3 (VPA, LTG, LEV) 6
3 (CBZ, LTG, LEV) 3
3 (VPA, CBZ, LEV) 1
3 (VPA, LCM, LEV) 1
Table 2
Seizure activity for monotherapy patients.
Number of patients Ongoing seizures/seizure free
4 Ongoing seizures
1 Seizure free (1–3 months)
2 Seizure free (>3 and <6 months)
6 Seizure free (6 months–1 year)
10 Seizure free (over 1 year)
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experimental nature of the LEV blood level determinations and
understood the difﬁculty encountered to have these performed. All
gave informed consent to have the levels measured, sent interstate
and understood that, at the time of measurement, there was no
established predetermined therapeutic level. The investigation
was undertaken in a prospective manner, using LEV levels as an
adjunct to routine patient care. LEV levels were compared to
seizure activity over a period of up to 1.8 years (0.2–1.8 years;
mean: 1.0  0.5) between 2010 and 2012.
All LEV levels were determined in a single laboratory by high
performance liquid chromatography (HPLC) analysis using solid
phase extraction of LEV from serum or plasma with inclusion
of an internal standard for accuracy. The column was washed
twice with various buffers to remove other AEMs. LEV was
extracted and quantitated using HPLC with ultraviolet (UV)
detection.14,15
Concomitant AEM levels were measured in a different
laboratory also run by the same pathologist. CBZ and valproate
(VPA) levels were measured using Fluorescence Polarisation.
Trough levels were taken. For CBZ, imprecision ranged between
2.9% and 3.0% and for VPA between 2.1% and 2.3%. The period used
to determine this, for both AEMs, was 28/05/2012 to 28/05/2013.
For CBZ, 688 measurements were made with the lowest mean
being 11.5 mmol/L and the highest mean being 62.0 mmol/L. For
VPA, 2024 measurements were made with the lowest mean being
233 mmol/L and the highest mean being 804 mmol/L.16 Free CBZ
and VPA levels were determined by ﬁltering serum through a
molecular ﬁlter to remove all proteins. This was then analysed on
the Roche Integra. Immunoassay control level 1 was used as a
control for ﬁltration and performed within the ﬁrst batch of sample
of the day. At least 0.4 mL, and up to 1.0 mL, of serum was
transferred to the inside of the reservoir. The reservoir was capped
and, along with the ﬁltrate cup labelled with the patient identiﬁer,
centrifuged, for 15 min at 3000 rpm, and the ﬁltrate analysed as
soon as possible.17 Lamotrigine (LTG) serum/plasma trough levels
were measured using HPLC with UV detection.18 All patients had
concomitant biochemical, renal, hepatic and haematological
parameters monitored to exclude confounding problems.
Seizure activity comprised ﬁve categories: ongoing seizures
(<one month seizure-free); one to three months seizure-freedom;
>three and <six months seizure-freedom; six months to one year
seizure-freedom; and >one year seizure-freedom. Concomitant
AEMs included CBZ, VPA, LTG and lacosamide (LCM). Both total and
free CBZ and VPA were measured (both VPA and CBZ being highly
protein bound19). LCM levels were unavailable. The importance of
free levels, when monitoring therapeutic drug levels in the
management of epilepsy, has been shown previously within
clinical management, to determine which AEM was the most likely
cause for AEM toxicity with polytherapy.20
Adopted therapeutic ranges were: 20–40 mg/L for LEV; 25–
50 mmol/L for CBZ total; 6–13 mmol/L for CBZ free; 300–
750 mmol/L for VPA total; 30–75 mmol/L for VPA free and 40–
60 mmol/L for LTG, acknowledging all but LEV were measured in
New South Wales laboratories and LEV was sent interstate to
Queensland (hence different units).
PWE were initiated on AEMs, other than LEV, with LEV added if
there was insufﬁcient efﬁcacy or adverse events. Where appropri-
ate, AEMs were reduced to LEV monotherapy. Doses were clinically
determined, aiming for maximal seizure control with minimal
adverse events, complemented by AEM levels.
In order to assess the relationship between LEV levels and LEV
doses, the concentration/dose ratio was calculated for LEV
monotherapy and LEV polytherapy patients.
Statistically signiﬁcant difference between groups was deter-
mined using the z-test for proportions, with a p-value <0.05 and atwo-tailed hypothesis suitable for non-normative data (http://
www.socscistatistics.com/tests/ztest/Default2.aspx, accessed on
29/11/2013). For mean concentration/dose ratios the t-test (with
a p-value <0.05 and a two-tailed hypothesis) was adopted for
determining statistically signiﬁcant differences between two
independent means (http://www.socscistatistics.com/tests/stu-
dentttest/Default2.aspx, accessed on 29/11/2013).
3. Results
Patients were aged 19–69 years (42  14) (Table 1). Thirty-one
(60%) were female. Twenty-seven (52%) had focal onset seizures, 21/
52 (40%) had primary generalised seizures and four (8%) had
unclassiﬁed seizures. Most common AEM combinations were LEV
with CBZ for focal epilepsy or VPA for generalised epilepsy (dual
therapy) and LEV with LTG and VPA (triple therapy) in generalised
epilepsy (Table 1).
Dosages were: 250–6000 mg/day for LEV (mean: 2919 mg/
day  1134); 600–1400 mg/day for CBZ (mean: 822 mg/day  227);
700–6000 mg/day for VPA (mean: 1931 mg/day  1561); 100–
1600 mg/day for LTG (mean: 546 mg/day  346) and 100–600 mg/
day for LCM (only two patients).
Twenty-three (44%) were on LEV monotherapy. Concomitant
AEM levels for three patients were excluded because insufﬁcient
levels precluded reliable data. LCM levels were unavailable thereby
preventing assessment of LEV interaction with LCM but LEV levels
for both PWE were therapeutic.
Absolute range of LEV levels was 2–100 mg/L (28  17) with
mean levels ranging from 4 to 71.5 mg/L (28.7  14). Thirty-two
(62%) had mean LEV levels within the therapeutic range. Thirty-six
(69%) were seizure-free (Table 2) (p < 0.05), 29 of them (81%) were
seizure-free for six months of whom 18 (62%) were seizure-free for
>one year (Table 3).
Fourteen (27%) had sub-therapeutic mean LEV levels and six
(12%) had supra-therapeutic mean LEV levels. 3 of 14 (21%) with
sub-therapeutic LEV levels had ongoing seizures (p = 0.0025). One
of six PWE (17%) with supra-therapeutic LEV levels experienced
Table 3
Seizure activity for polytherapy patients.
Number of patients Ongoing seizures/seizure free
12 Ongoing seizures
3 Seizure free (1–3 months)
1 Seizure free (>3 and <6 months)
5 Seizure free (6 months–1 year)
8 Seizure free (over 1 year)
D. Stepanova, R.G. Beran / Seizure 23 (2014) 371–376 373symptoms of toxicity (p = 0.0209). This patient reported increased
seizure rate with exacerbation interpreted as toxicity and the
relevant LEV level was 86 mg/L.
Twenty-three (44%) were on LEV monotherapy of whom 16
(70%) had therapeutic mean LEV, 13 of whom (81%) were seizure-
free (p = 0.0004) (5/13 (38%) for >six months and 6/13 (46%) for
>one year), demonstrating the value of the adopted therapeutic
window. Six of these 23 patients (26%) had sub-therapeutic mean
LEV levels of whom one (17%) had ongoing seizures (p = 0.0209). 1
of 23 (4%) had supra-therapeutic mean LEV levels without toxicity
suggesting that higher dosages may still be possible.
Twenty-nine (56%) were taking concomitant AEMs with 16/29
(55%) having therapeutic mean LEV levels (comparable to those
on monotherapy (p = 0.2891)). Seven of these 16 (44%) were0
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Fig. 2. Correlation between totaseizure-free (1/7 (14%) for >six months and 4/7 (57%) for >one
year) (Fig. 1).
Eleven of 29 PWE (38%) were taking CBZ, all of whom had
therapeutic total and free mean CBZ levels. Seven (64%) were
seizure-free (3/7 (43%) for >six months and 2/7 (29%) for >one
year). Four (36%) had therapeutic mean LEV levels and 2/4 (50%)
were seizure free (one (50%) for >one year). Two (18%) had supra-
therapeutic mean LEV levels and both were seizure free for >six
months (without toxicity). Five (45%) had sub-therapeutic mean
LEV levels with one (20%) seizure-free for >six months and one
(20%) seizure-free for >one year. The remaining three PWE had
ongoing seizures (Fig. 2).
14 of 29 (48%) PWE were taking VPA, all with therapeutic total
mean VPA levels. Eight (57%) were seizure-free (2/8 (25%) for >six
months and 5/8 (63%) for >one year). Nine (64%) had supra-
therapeutic free mean VPA levels and 6/9 (67%) were seizure-free
(1/6 (17%) for >six months and 4/6 (67%) for >one year). No
symptoms of toxicity were reported for these patients. Five (36%)
had therapeutic free mean VPA levels and 2/5 (40%) were seizure-
free (one (50%) for >six months and one (50%) for >one year). Nine
(64%) had therapeutic mean LEV levels and 3/9 (33%) were seizure-
free (1/3 (33%) for >six months and 2/3 (67%) for >one year).
Three (21%) had sub-therapeutic mean LEV levels, all of whom
were seizure-free (2/3 (67%) for >one year). Two (14%) had20 25 30
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seizure-free for >six months and one (50%) for >one year. No
symptoms of toxicity were reported for these patients (Fig. 3).
Discrepancy between total and free CBZ and VPA levels was
reviewed. None of the CBZ treated PWE showed discrepancy but 8
of 14 PWE (57%) on VPA had a discrepancy between total and free
levels.
13 of 29 (45%) PWE were taking LTG. Seven (54%) had
therapeutic mean LTG levels and 2/7 (29%) were seizure-free
(one (50%) for >one year). Three (23%) had sub-therapeutic mean
LTG levels, two (67%) of whom were seizure-free (1/3 (33%) for
>six months). Three (23%) had supra-therapeutic mean LTG levels
with 1/3 (33%) being seizure-free (>one year). One of these three
(33%) experienced symptoms of toxicity. This patient reported
strange feelings, not thought to be seizures, interpreted as drug
toxicity, with LTG level of 85.9 mmol/L. 8 of 13 (62%) PWE had
therapeutic mean LEV levels and 1/8 (13%) was seizure-free (>one
year) which was statistically signiﬁcant (p = 0.0027). Two (15%)
had supra-therapeutic mean LEV levels (one patient reporting
increased seizure rate interpreted as toxicity) and one of these
(50%) was seizure-free (>six months). Three (23%) had sub-
therapeutic mean LEV levels and all three were seizure-free (1/3
(33%) for >one year) (Fig. 4).
Eleven of 52 PWE (21%) were on three AEMs (Table 1). Seven
(64%) had therapeutic mean LEV levels and one of whom (14%) was
seizure-free (>one year) which was statistically signiﬁcant(p = 0.0076). Three (27%) had sub-therapeutic mean LEV levels
and all three were seizure-free (1/3 (33%) for >one year). One (9%)
PWE had supra-therapeutic mean LEV levels, was seizure-free
(>six months) and had no toxicity.
Nine of 11 PWE (82%) were taking LTG, ﬁve of whom (56%) had
therapeutic mean LTG levels with 2/5 (40%) seizure-free (one for
>one year). Two (22%) had sub-therapeutic mean LTG levels and
both were seizure-free (one (50%) for >six months) while two
(22%) had supra-therapeutic mean LTG levels, both with ongoing
seizures and no toxicity.
Eight of 11 PWE (72%) were taking VPA, all having therapeutic
total mean VPA levels and 3/8 (38%) were seizure-free (2/3 (67%)
for >1 year). Four (50%) had therapeutic free mean VPA levels with
3/4 (75%) having ongoing seizures. Four (50%) PWE had supra-
therapeutic mean free VPA levels and 2/4 (50%) were seizure-free
(one (50%) for >one year), all without toxicity.
Four of 11 PWE (36%) were taking CBZ all with therapeutic total
and free mean CBZ levels. Two (50%) were seizure-free (one (50%)
for >six months).
Mean concentration/dose ratios were compared for LEV
monotherapy and polytherapy. The mean concentration/dose
ratio for polytherapy was signiﬁcantly lower than was the mean
ratio for monotherapy (p = 0.0090). The mean LEV dose for
monotherapy patients was 2401.8 mg/day (mean LEV level was
28.6 mg/L) and for polytherapy was 3077.0 mg/day (mean LEV
level was 28.9 mg/L). The mean LEV dose for monotherapy patients
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(p = 0.0226), suggesting a need for higher LEV dosages in PWE who
are on polytherapy.
4. Discussion
LEV reduced seizure frequency by 50% in a cohort of 1541 PWE
with seizure-freedom in 60%.21 In a study of 228 PWE,
approximately 50% were seizure-free for >one year on a median
dose of LEV of 1000 mg/day.22 The current study reports 69%
seizure-free, of whom 81% were seizure-free for six months and
62% >one year, suggesting improved efﬁcacy when clinical
decisions are complemented by blood level determination.
Recommended LEV dosages range from 1000 to 4000 mg/day23
with median dosage in the pivotal trials being 3000 mg/day.9,24 In
this study, LEV doses range from 250 to 6000 mg/day (mean:
2778 mg/day) suggesting the application of blood levels, com-
plementing clinical decision-making, allowed increased dosages in
some patients but a mean dosage comparable to that within the
literature.
LEV is considered to be an effective add-on treatment across
various seizure types in patients with refractory epilepsy.25 The
PWE in this study were prescribed LEV as adjunctive treatment and
converted to monotherapy when possible. LEV monotherapy,
monitored with blood levels, was more effective than was LEV with
polypharmacy and demonstrated reduced concentration/dose
ratio. 23 of the 52 PWE (44%) were on LEV monotherapy, 16 of
whom (70%) had mean LEV levels within the therapeutic range and
13 of these 16 (81%) were seizure-free with 11/13 (85%) seizure-
free for >six months and 6/13 (46%) >one year. The number of PWE
who were seizure-free was statistically signiﬁcantly higher than
those with ongoing seizures (p = 0.0004).
Ben-Menachem and Falter26 showed LEV monotherapy pro-
duced approximately 74% median reduction in partial seizure
frequency. Korby et al.27 showed 76% of LEV monotherapy patients
were seizure-free, compared to 36% with polytherapy. With
therapeutic LEV levels, 81% monotherapy and 44% polytherapy
PWE were seizure-free (85% and 71% >six months, respectively)
indicating enhanced efﬁcacy when combining clinical decision-
making with blood levels.
This study demonstrated reduced LEV efﬁcacy with polyther-
apy, requiring higher concentration/dose ratios and suggested LEV
was affected by concomitant AEMs. The present study included 11/
52 (21%) PWE requiring three AEMs (11/29 (38%) of those on
polypharmacy) reﬂective of a more refractory spectrum of epilepsy
in this cohort. The use of LEV levels, in conjunction with levels of
concomitant AEMs, allows more speciﬁc adaptation of dosage
regimen to patient needs. In the present study, dosages up to
6000 mg LEV were used without toxicity.
29 of 52 PWE (56%) were taking concomitant AEMs, of whom 16
(55%) had LEV levels within range and 7/16 (44%) were seizure-
free, with 5/7 (71%) seizure-free for >six months and 4/7 (57%)
>one year. These data were comparable with the monotherapy
cohort.
This study suggested drug interactions between LEV and
concomitant AEMs thereby confounding therapeutic levels with
polypharmacy. Sixteen out of 29 (55%) PWE on polypharmacy
had mean LEV levels within range compared with 70% of PWE on
LEV monotherapy. Fourteen of 29 patients (48%) were taking
VPA, of whom nine (64%) had mean LEV levels within range.
Thirteen of 29 PWE (45%) were taking LTG, of whom eight (62%)
had mean LEV levels within range. While all 11 PWE on CBZ had
therapeutic total and free CBZ levels, 5/11 (46%) had sub-
therapeutic LEV of whom 2/5 (40%) were still seizing. This
suggests CBZ may affect LEV metabolism although the mecha-
nism is unclear.The effect of LEV on concomitant AEMs also requires consider-
ation. All PWE on CBZ (11/52) maintained therapeutic total and
free CBZ levels, suggesting LEV has little effect on CBZ metabolism,
noting that CBZ metabolism depends on the hepatic cytochrome
p450 system which is not involved in LEV metabolism.2,28 Total
VPA levels were therapeutic for all those on VPA (14/52) but 5/14
(36%) had therapeutic VPA free levels and 9/14 (64%) had supra-
therapeutic free levels, which suggests that LEV may impede VPA
protein binding. The reason for this is unclear as LEV has minimal
protein binding.3Many clinicians ignore VPA levels or rely more on
free VPA levels29 which, this study suggests, may be affected by
concomitant LEV administration.
The relationship between LEV and LTG co-administration is less
predictable with half (7/13) maintaining therapeutic LTG levels
and equal numbers (3/13) having either supra- or sub-therapeutic
LTG levels. LEV and LCM interaction could not be adequately
assessed but both patients had therapeutic LEV levels.
This study also suggests interactions between LEV and
concomitant AEMs, via the concentration/dose ratio, with a lower
ratio for polytherapy patients (p = 0.0090). The mean LEV dose for
monotherapy was 2401.8 mg/day compared with 3077.0 mg/day
for polytherapy patients (p = 0.0226). The mean LEV levels for both
monotherapy and polytherapy were 29 mg/L, indicating that
patients on polytherapy required higher dose of LEV to achieve
similar blood levels.
This study demonstrated that the adopted LEV therapeutic
range (20–40 mg/L) assisted in decision-making and better
management of epilepsy, especially with monotherapeutic LEV.
40 mg/L may not be the maximal therapeutic level but allowed
most PWE to experience reduced seizures with minimal adverse
events.
This study reported signiﬁcant possible drug interactions
between LEV and concomitant AEMs, something, hitherto,
considered insigniﬁcant but which may further explain impaired
efﬁcacy of LEV with polypharmacy. It showed that the interactions
between LEV and concomitant AEMs may be unpredictable (as
with LTG) providing additional support for use of blood level
determination of both LEV and concomitant AEMs when treating
PWE.
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